0
Original Investigation | Socioeconomics and Health Services

The Potential Association Between Postmenopausal Hormone Use and Primary Open-Angle Glaucoma

Paula Anne Newman-Casey, MD, MS1; Nidhi Talwar, MA1; Bin Nan, PhD2; David C. Musch, PhD, MPH1,3; Louis R. Pasquale, MD4,5; Joshua D. Stein, MD, MS1
[+] Author Affiliations
1Department of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor
2Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor
3Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor
4Department of Ophthalmology, Harvard Medical School, Cambridge, Massachusetts
5Department of Medicine, Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical School, Cambridge, Massachusetts
JAMA Ophthalmol. 2014;132(3):298-303. doi:10.1001/jamaophthalmol.2013.7618.
Text Size: A A A
Published online

Importance  Retinal ganglion cells are known to express estrogen receptors and prior studies have suggested an association between postmenopausal hormone (PMH) use and decreased intraocular pressure, suggesting that PMH use may decrease the risk for primary open-angle glaucoma (POAG).

Objective  To determine whether the use of 3 different classes of PMH affects the risk for POAG.

Design, Setting, and Participants  Retrospective longitudinal cohort analysis of claims data from women 50 years or older enrolled in a US managed-care plan for at least 4 years in which enrollees had at least 2 visits to an eye care provider during the period 2001 through 2009.

Exposure  Postmenopausal hormone medications containing estrogen only, estrogen + progesterone, and estrogen + androgen, as captured from outpatient pharmacy claims over a 4-year period.

Main Outcomes and Measures  Hazard ratios (HRs) for developing incident POAG.

Results  Of 152 163 eligible enrollees, 2925 (1.9%) developed POAG. After adjustment for confounding factors, each additional month of use of PMH containing estrogen only was associated with a 0.4% reduced risk for POAG (HR, 0.996 [95% CI, 0.993-0.999]; P = .02). The risk for POAG did not differ with each additional month of use of estrogen + progesterone (HR, 0.994 [95% CI, 0.987-1.001]; P = .08) or estrogen + androgen (HR, 0.999 [95% CI, 0.988-1.011]; P = .89).

Conclusions and Relevance  Use of PMH preparations containing estrogen may help reduce the risk for POAG. If prospective studies confirm the findings of this analysis, novel treatments for this sight-threatening condition may follow.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Figure.
Selection of Beneficiaries for Analysis

The 152 163 eligible for analysis includes 70 292 women using postmenopausal hormone (PMH) and 81 871 women not using PMH. Some women appear in more than 1 group because they used more than 1 type of PMH. CPT indicates Current Procedural Terminology; PCOS, polycystic ovarian syndrome; POAG, primary open-angle glaucoma; SERM, serum estrogen receptor modulator.

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Jobs
brightcove.createExperiences();